Form 8-K Aclaris Therapeutics, For: Nov 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Goldman Comments on Aclaris Therapeutics (ACRS), Shares up 33% Today, Up 245% Over Past 30 Days
November 19, 2024 11:07 AM ESTGoldman Comments on Aclaris Therapeutics (NASDAQ: ACRS)
The analyst comments "This morning, ACRS announced it has entered into a license agreement with Biosion for global rights (excluding China) to BSI-045B (also known as TQC2731), an anti-TSLP monoclonal antibody (mAb), and BSI-502, an anti-TSLP plus anti-IL4R... More
Leerink Partners Upgrades Aclaris Therapeutis (ACRS) to Outperform, Shares +20% in Premarket Session
November 19, 2024 7:06 AM EST(Updated - November 19, 2024 7:19 AM EST)
Leerink Partners analyst Thomas J. Smith upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Market Perform to Outperform with a price target of $7.00 (from $2.00).
The analyst comments "We are upgrading ACRS to Outperform (from Market Perform) and raising our PT... More
Piper Sandler Upgrades Aclaris Therapeutis (ACRS) to Overweight, PT $13
November 18, 2024 2:54 PM ESTPiper Sandler analyst Christopher Raymond upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Neutral to Overweight with a price target of $13.00 (from $3.00).
The analyst comments "Upgrading ACRS shares to Overweight after what we see as a transformative deal to acquire two novel I&I... More
Stifel Reiterates Hold Rating on Aclaris Therapeutis (ACRS)
November 18, 2024 12:34 PM ESTStifel analyst Alex Thompson reiterated a Hold rating and $3.00 price target on Aclaris Therapeutis (NASDAQ: ACRS)
The analyst comments "Aclaris announced a licensing agreement with Biosion to acquire ex-China rights to a clinical stage TSLP mAb (BSI-045B) and a preclinical TSLPxIL-4R bispecific (BSI-502). The... More
